African Journal of
Biotechnology

  • Abbreviation: Afr. J. Biotechnol.
  • Language: English
  • ISSN: 1684-5315
  • DOI: 10.5897/AJB
  • Start Year: 2002
  • Published Articles: 12486

Full Length Research Paper

Predominance of N-acetyl transferase 2 slow acetylator alleles in children less than ten years experiencing adverse treatment events following artemisinin-based combination therapy in North and South West Regions of Cameroon

Jean P. C. Kengne
  • Jean P. C. Kengne
  • The Biotechnology Center, University of Yaounde I, Yaounde, Cameroon.
  • Search for this author on:
  • Google Scholar
Akindeh M. Nji
  • Akindeh M. Nji
  • The Biotechnology Center, University of Yaounde I, Yaounde, Cameroon.
  • Search for this author on:
  • Google Scholar
Innocent M. Ali
  • Innocent M. Ali
  • The Biotechnology Center, University of Yaounde I, Yaounde, Cameroon.
  • Search for this author on:
  • Google Scholar
Olivia A. Achonduh
  • Olivia A. Achonduh
  • The Biotechnology Center, University of Yaounde I, Yaounde, Cameroon.
  • Search for this author on:
  • Google Scholar
Ekollo M. Aristid
  • Ekollo M. Aristid
  • The Biotechnology Center, University of Yaounde I, Yaounde, Cameroon.
  • Search for this author on:
  • Google Scholar
Wilfred F. Mbacham
  • Wilfred F. Mbacham
  • The Biotechnology Center, University of Yaounde I, Yaounde, Cameroon.
  • Search for this author on:
  • Google Scholar


  •  Received: 18 January 2016
  •  Accepted: 10 May 2016
  •  Published: 22 June 2016

References

Achonduh OA, AtoghoTB, Mbulli IA, Chedjou JP, Achu M, Nji AM, Fokou E, Kamgue E, Veyee V, Karana O, Sahfe D, Mbacham WF (2013). Adverse events clustering with NAT2 slow metabolisers following deparasitization in children in Bangolan, NWR Cameroon. J. Life Sci. 7(7):742.
 

Adjei GO, Goka BQ, Rodrigues OP, Høgberg LC, Alifrangis M, Kurtzhals JA (2009). Amodiaquine-associated adverse effects after inadvertent overdose and after a standard therapeutic dose. Ghana Med. J. 43(3):135-138.

  
 

Agundez JA (2008). Polymorphisms of human N-acetyltransferases and cancer risk. Curr. Drug Metabol. 9(6):520-531.
Crossref

  
 

AlKadi HO (2007). Antimalarial drug toxicity: A review. Chemotherapy 53(6):385-391.
Crossref

  
 

Boukouvala BSE (2005). Structural analysis of the genes for human arylamine N-acetyltransferases and characterization of alternative transcripts. Basic Clin. Pharmacol. Toxicol. 96(5):343-351.
Crossref

  
 

Chen B, Zhang WX, Cai WM (2006). The influence of various genotypes on the metabolic activity of NAT2 in a Chinese population. Eur. J. Clin. Pharmacol. 62(5):355-359.
Crossref

  
 

Chen M, Xia B, Chen B, Guo Q, Li J, Ye M, Hu Z (2007). N-acetyltransferase 2 slow acetylator genotype associated with adverse effects of sulphasalazine in the treatment of inflammatory bowel disease. Can. J. Gastroenterol. 21(3):155-158.
Crossref

  
 

Furet Y, Bechtel Y, Le Guellec C, Bechtel PR, Autret-Leca E, Paintaud G (2002). Clinical relevance of N-acetyltransferase type 2 (NAT2) genetic polymorphism. Therapie 57(5):427-431.

  
 

Garcia-Closas M, Malats N, Silverman D, Dosemeci M, Kogevinas M, Hein DW, Tardón A, Serra C, Carrato A, García-Closas R, Lloreta J (2005). NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses. Lancet 366(9486):649-659.
Crossref

  
 

Gupta VH, Amarapurkar DN, Singh M, Sasi P, Joshi JM, Baijal R, Ramegowda PH, Amarapurkar AD, Joshi K, Wangikar PP (2013). Association of N-acetyltransferase 2 and cytochrome P450 2E1 gene polymorphisms with antituberculosis drug-induced hepatotoxicity in Western India. J. Gastroenterol. Hepatol. 28(8):1368-1374.
Crossref

  
 

Hein DW (2002). Molecular genetics and function of NAT1 and NAT2: role in aromatic amine metabolism and carcinogenesis. Mutat. Res. 506-507:65-77.
Crossref

  
 

Huang YS, Chern HD, Su WJ, Wu JC, Lai SL, Yang SY, Chang FY, Lee SD (2002). Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis. Hepatology 35(4):883-889.
Crossref

  
 

Ingelman-Sundberg M (2005). Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogen. J. 5(1):6-13.
Crossref

  
 

Kang TS, Jin SK, Lee JE, Woo SW, Roh J (2009). Comparison of genetic polymorphisms of the NAT2 gene between Korean and four other ethnic groups. J. Clin. Pharm. Ther. 34(6):709-718.
Crossref

  
 

Kleinschmidt I, Omumbo J, Briet O, Van De Giesen N, Sogoba N, Mensah NK, Windmeijer P, Moussa M, Teuscher T (2001). An empirical malaria distribution map for West Africa. Trop. Med. Int. Health 6(10):779-786.
Crossref

  
 

Kumagai S, Komada F, Kita T, Morinobu A, Ozaki S, Ishida H, Sano H, Matsubara T, Okumura K (2004). N-acetyltransferase 2 genotype-related efficacy of sulfasalazine in patients with rheumatoid arthritis. Pharm. Res. 21(2):324-329.
Crossref

  
 

Ladero JM (2008). Influence of polymorphic N-acetyltransferases on non-malignant spontaneous disorders and on response to drugs. Curr. Drug Metabol. 9(6):532-537.
Crossref

  
 

Lee SW, Chung L, Huang HH, Chuang TY, Liou YH, Wu L (2010). NAT2 and CYP2E1 polymorphisms and susceptibility to first-line anti-tuberculosis drug-induced hepatitis. Int. J. Tuberc. Lung Dis. 14(5):622-626.

  
 

Nebert DW (1997). Polymorphisms in drug-metabolizing enzymes: what is their clinical relevance and why do they exist. Am. J. Hum. Genet. 60(2):265-271.

  
 

Pirmohammed MAK, Dodoo ANO, Winstanley P (2007). Pharmacovigilance in developing countries: Requires collaboration between stakeholders to develop novel models of funding. Br. Med. J. 335(7618):462-462.
Crossref

  
 

Plowe CV, Djimde A, Bouare M, Doumbo O, Wellems TE (1995). Pyrimethamine and proguanil resistance-conferring mutations in Plasmodium falciparum dihydrofolate reductase: polymerase chain reaction methods for surveillance in Africa. Am. J. Trop. Med. Hyg. 52(6):565-568.

  
 

Rychlik-Sych M, Skrêtkowicz J, Gawro-ska-Szklarz B, Górnik W, Sysa-Jêdrzejowska A, Skrêtkowicz-Szarmach K (2006). Acetylation genotype and phenotype in patients with systemic lupus erythematosus. Pharmacol. Rep. 58(1):22-29.

  
 

Sim E, Lack N, Wang CJ, Long H, Westwood I, Fullam E, Kawamura A (2008). Arylamine N-acetyltransferases: structural and functional implications of polymorphisms. Toxicology 254(3):170-183.
Crossref

  
 

Vatsis KP, Weber WW, Bell DA, Dupret JM, Evans DA, Grant DM, Hein DW, Lin HJ, Meyer UA, Relling MV, Sim E (1995). Nomenclature for N-acetyltransferases. Pharmacogenet Genomics 5(1):1-17.
Crossref

  
 

Walraven JM, Zang Y, Trent JO, Hein DW (2008). Structure/Function Evaluations of Single Nucleotide Polymorphisms in Human N-Acetyltransferase 2. Curr. Drug Metabol. 9(6):471-486.
Crossref

  
 

WHO (2002). The importance of pharmacovigilance: safety monitoring of medicinal products. In. Geneva.

  
 

Wilkinson GR (2005). Drug metabolism and variability among patients in drug response. New Eng. J. Med. 352(21):2211-2221.
Crossref

  
 

Yokogawa K, Nakaharu T, Ishizaki J, Ozaki E, Takeda Y, Mabuchi H, Matsushita R, Kimura K, Nakashima E, Ichimura F, Miyamoto KI (2001). Kinetic phenotypic diagnosis of N-acetylation polymorphism in patients based on ratio of urinary metabolites of salicylazosulfapyridine. Int. J. Pharm. 229(1-2):183-191.
Crossref

  

 

Copyright © 2024 Author(s) retain the copyright of this article.

This article is published under the terms of the Creative Commons Attribution License 4.0

Back to Vol. 15 No. 25
Back to articles
SUBSCRIBE TO RSS
SUBMIT MANUSCRIPT
CONFERENCES